We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+0.93%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$385M
AUM Growth
-$76.2M
Cap. Flow
-$70.4M
Cap. Flow %
-18.28%
Top 10 Hldgs %
44.6%
Holding
124
New
35
Increased
20
Reduced
21
Closed
33

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$16.8M
2
LLY icon
Eli Lilly
LLY
+$15.1M
3
SHPG
Shire pic
SHPG
+$13.7M
4
AMGN icon
Amgen
AMGN
+$13.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.79M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$33.6M
2
BIIB icon
Biogen
BIIB
+$18M
3
ORA icon
Ormat Technologies
ORA
+$13.3M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$6.65M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.41M

Sector Composition

Rank Sector Weight
1 Healthcare 77%
2 Technology 4.38%
3 Communication Services 1.71%
4 Consumer Discretionary 1.16%
5 Financials 0.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENDP
51
DELISTED
Endo International plc
ENDP
$2.34M 0.61%
+150,000
New +$3.11M
CYNA
52
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$2.25M 0.58%
134,037
– –
FWP
53
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.21M 0.57%
17,357
– –
FOMX
54
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.17M 0.56%
342,000
– –
ORBK
55
DELISTED
Orbotech Ltd
ORBK
$2.15M 0.56%
84,210
+18,500
+28% +$469K
CLSD
56
DELISTED
Clearside Biomedical
CLSD
$2.1M 0.55%
+20,000
New +$2.1M
ALDX icon
57
Aldeyra Therapeutics
ALDX
$92.9M
$2.1M 0.54%
368,500
+130,000
+55% +$726K
SAGE
58
DELISTED
Sage Therapeutics
SAGE
$2.09M 0.54%
69,500
-53,500
-43% -$1.78M
DERM
59
DELISTED
Dermira, Inc.
DERM
$2.05M 0.53%
70,000
-50,000
-42% -$1.38M
DBVT
60
DBV Technologies
DBVT
$799M
$1.98M 0.51%
+6,061
New +$1.96M
PRTK
61
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.95M 0.51%
+140,000
New +$2.06M
KDNY
62
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.92M 0.5%
34,000
– –
RCKT icon
63
Rocket Pharmaceuticals
RCKT
$340M
$1.86M 0.48%
62,500
– –
BLUE
64
DELISTED
bluebird bio
BLUE
$1.73M 0.45%
3,088
+772
+33% +$437K
SMMT icon
65
Summit Therapeutics
SMMT
$10.4B
$1.56M 0.41%
197,450
-1,413
-0.7% -$11.5K
PDSB icon
66
PDS Biotechnology
PDSB
$38.4M
$1.52M 0.39%
7,500
– –
MRNS
67
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.49M 0.39%
292,661
+149,934
+105% +$2.76M
EGLT
68
DELISTED
Egalet Corporation
EGLT
$1.45M 0.38%
292,500
– –
KYNB
69
Kyntra Bio
KYNB
$27.2M
$1.41M 0.37%
+3,428
New +$1.57M
BHC icon
70
Bausch Health
BHC
$2.57B
$1.38M 0.36%
68,500
– –
PVLA
71
Palvella Therapeutics
PVLA
$1.99B
$1.3M 0.34%
10,125
– –
IMDZ
72
DELISTED
Immune Design Corp.
IMDZ
$1.25M 0.32%
153,000
– –
PTCT icon
73
PTC Therapeutics
PTCT
$5.64B
$1.23M 0.32%
174,461
-75,539
-30% -$554K
TRIL
74
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.19M 0.31%
132,300
– –
VTGN icon
75
VistaGen Therapeutics
VTGN
$9.89M
$1.15M 0.3%
+9,803
New +$1.12M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sphera Funds Management held 124 positions worth $385M, down 17% from $461M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management withdrew a net $70.4M in Q2 2016, closing 33 positions and reducing 21 holdings. Its most notable exit was Ormat Technologies, an estimated $13.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 62% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sphera Funds Management opened a new position in GSK worth $6.39M.

  • Sphera Funds Management's largest Q2 2016 buy was GSK: 318,630 shares worth $6.39M.
  • Sphera Funds Management added most to Shire pic in Q2 2016, an estimated $13.7M increase.
  • Sphera Funds Management's biggest Q2 2016 reduction was Pfizer, cutting an estimated $33.6M.
  • Sphera Funds Management fully exited Ormat Technologies in Q2 2016, selling an estimated $13.3M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $385M portfolio in Q2 2016.
  • Sphera Funds Management opened 35 new positions and closed 33 in Q2 2016.
  • Sphera Funds Management's portfolio value fell 17% quarter-over-quarter to $385M.

Based on Sphera Funds Management's 13F filing for Q2 2016, filed 10 Aug 2016.